B020004J07Rik Inhibitors
Chemical inhibitors of PRAME like 17 can disrupt its function through various intracellular signaling pathways and protein interactions. Staurosporine and Dasatinib are kinase inhibitors that can prevent the phosphorylation of PRAME like 17, or of other proteins within its signaling cascade. By blocking this post-translational modification, these inhibitors can attenuate the activity of PRAME like 17. Similarly, U0126 and PD98059 specifically target the MEK enzymes in the MAPK pathway, which can result in the deactivation of downstream ERK signaling, potentially reducing the functional capabilities of PRAME like 17. The PI3K/AKT/mTOR pathway is another target, with LY294002 and Wortmannin functioning as PI3K inhibitors, and Rapamycin targeting mTOR directly. Inhibition of this pathway can lead to a decrease in PRAME like 17 activity if its function is reliant on this signaling mechanism.
Compounds like Trichostatin A take a different approach by inhibiting histone deacetylases, potentially altering the chromatin landscape and affecting PRAME like 17 interactions with DNA or DNA-bound proteins. On the other hand, SP600125 and SB203580 are inhibitors of the JNK and p38 MAP kinase, respectively, and can suppress the activation of transcription factors or other proteins that regulate the function of PRAME like 17. Lastly, Lactacystin and Bortezomib inhibit the proteasome, leading to the accumulation of proteins within the cell that can act as natural inhibitors of PRAME like 17, hence indirectly reducing its activity. Through these diverse mechanisms, each chemical inhibitor can contribute to the downregulation of PRAME like 17 activity within cellular contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. PRAME like 17 may require phosphorylation for its activity, by kinases that can be inhibited by Staurosporine. Inhibition of these kinases leads to decreased phosphorylation and subsequent inhibition of PRAME like 17 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, and PRAME like 17 could rely on MEK/ERK pathway for its function. By inhibiting MEK, U0126 prevents activation of ERK, which may be necessary for PRAME like 17 signaling, thus leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K), which are involved in the PI3K/AKT/mTOR pathway. PRAME like 17 activity may be dependent on signaling through this pathway, and inhibition by LY294002 would disrupt its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR, a central protein in the PI3K/AKT/mTOR pathway. Inhibition of mTOR can lead to reduced activity of proteins regulated by this pathway, which could include PRAME like 17, thereby inhibiting its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. By blocking PI3K, it inhibits the downstream PI3K/AKT/mTOR signaling, which could be essential for the activity of PRAME like 17, resulting in its functional inhibition. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It can alter chromatin structure and affect the function of transcription factors and other proteins interacting with DNA. PRAME like 17, being a protein that may interact with chromatin, could be functionally inhibited by the altered DNA-protein interaction landscape caused by Trichostatin A. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which could be involved in the signaling pathways regulating PRAME like 17. Inhibiting JNK could prevent activation of transcription factors or other proteins that are required for PRAME like 17 function, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. As MAP kinase pathways can regulate various protein activities, inhibition of p38 MAP kinase might lead to the inhibition of PRAME like 17 function if it is regulated by p38 MAPK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 specifically inhibits MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 could block the activation of PRAME like 17 if its function is mediated through the MAPK signaling pathway. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor. By inhibiting the proteasome, it prevents the degradation of ubiquitinated proteins, which could lead to accumulation of regulatory proteins that inhibit PRAME like 17 function. | ||||||